Your shopping cart is empty!
Janssen Pharmaceuticals Wins FDA Approval For Erleada (apalutamide) Tablets For The Treatment Of Prostate Cancer
- Hits: 504
Janssen Pharmaceuticals wins FDA approval for Erleada Tablets for the treatment of Prostate Cancer
A new drug that can stall the progression of a particularly hard-to-treat form of prostate cancer has been approved for use by U.S. health officials.
Company: Janssen Pharmaceuticals, Inc.
Brand Name: Erleada
Generic Name: apalutamide
Dosage Form: Tablets
Treatment for: Prostate Cancer
General information about Erleada
Erleada (apalutamide) is an oral androgen receptor inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC).
Erleada (apalutamide) has shown breakthrough effectiveness in keeping prostate cancer from spreading for two years in men whose disease had not yet traveled to other parts of their body.